Verus Capital Partners’s Novo Nordisk NVO Stock Holding History

Verus Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	+7,829	New	+$336K	0.02%	345
2026 Q1	–	Sell	-4,027	Closed	-$205K	–	489
2025 Q4	$205K	Sell	4,027 -503	-11%	-$25.7K	0.01%	427
2025 Q3	$251K	Sell	4,530 -1,454	-24%	-$85.1K	0.02%	353
2025 Q2	$413K	Buy	5,984 +2,296	+62%	+$156K	0.04%	238
2025 Q1	$256K	Sell	3,688 -201	-5%	-$16.6K	0.03%	304
2024 Q4	$326K	Sell	3,889 -1,334	-26%	-$144K	0.03%	264
2024 Q3	$622K	Buy	5,223 +748	+17%	+$99.8K	0.06%	169
2024 Q2	$637K	Sell	4,475 -1,014	-18%	-$134K	0.07%	164
2024 Q1	$705K	Sell	5,489 -665	-11%	-$79.2K	0.08%	149
2023 Q4	$637K	Buy	6,154 +1,507	+32%	+$149K	0.08%	143
2023 Q3	$423K	Buy	+4,647	New	+$409K	0.06%	182
2020 Q1	$78K	Hold	2,600	–	–	0.02%	372
2019 Q4	$75K	Buy	+2,600	New	+$72K	0.02%	469

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Verus Capital Partners's NVO Position: Q2 2026 in Review

Verus Capital Partners opened a new position in Novo Nordisk (NVO) in Q2 2026: 7,829 shares worth $375K. The stake represents 0.02% of the portfolio and ranks #345 among its holdings. This is a return to the name: Verus Capital Partners previously reported a position in NVO as recently as Q4 2025.

Verus Capital Partners first reported a position in NVO in Q4 2019 and has held it in 13 quarters since. The position peaked at $705K in Q1 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Verus Capital Partners held 7,829 shares of Novo Nordisk worth $375K as of Q2 2026.
Novo Nordisk was a new Verus Capital Partners position in Q2 2026.
Novo Nordisk made up 0.02% of Verus Capital Partners's portfolio in Q2 2026, its #345 holding.
Verus Capital Partners first reported a position in Novo Nordisk in Q4 2019 and has held it in 13 quarters since.
Verus Capital Partners's Novo Nordisk position peaked at $705K in Q1 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.